Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

XTL Biopharmaceuticals Sponsored ADR (XTLB) Stock Price & Analysis

148 Followers

XTLB Stock Chart & Stats

$1.60-$0.04(-2.44%)
At close: 4:00 PM EST
$1.5$2$2.5$3Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.54 - $1.73
52-Week Range
$1.52 - $5.64
Previous Close
$1.64
Volume
N/A
Average Volume (3M)
8,461
Market Cap
$7.81M
Enterprise Value
$5.24T
Total Cash (Recent Filing)
$1.14M
Total Debt (Recent Filing)
$138.00K
Price to Earnings (P/E)
―
Beta
1.14
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Pipeline Development

The company's focus on developing therapeutic candidates for unmet medical needs in autoimmune diseases and oncology indicates a strong potential for future growth and market relevance, as successful drug development can lead to significant revenue streams from licensing and sales.

Strategic Collaborations

Strategic collaborations with pharmaceutical companies for co-development or out-licensing of drug candidates can provide XTL Biopharmaceuticals with essential funding, expertise, and market access, enhancing its ability to bring products to market and generate revenue.

Low Debt Profile

Maintaining a low debt profile provides XTL Biopharmaceuticals with greater financial flexibility and reduces the risk of financial distress, allowing the company to focus resources on R&D and strategic initiatives without the burden of high-interest obligations.

Bears Say

Negative Cash Flow

Persistent negative cash flow highlights liquidity challenges, limiting the company's ability to invest in growth opportunities and sustain operations without external funding, which could hinder long-term strategic objectives and financial stability.

High Liabilities

A high level of liabilities compared to assets indicates financial instability, which could constrain XTL Biopharmaceuticals' ability to secure additional financing or invest in R&D, potentially impacting its ability to advance its drug pipeline and achieve profitability.

Persistent Net Losses

Ongoing net losses and negative EBIT margins reflect operational inefficiencies and a lack of revenue generation, posing a challenge to achieving profitability and requiring the company to rely on external funding to sustain operations and invest in future growth.

XTL Biopharmaceuticals Sponsored ADR News

XTLB FAQ

What was XTL Biopharmaceuticals Sponsored ADR’s price range in the past 12 months?
XTL Biopharmaceuticals Sponsored ADR lowest stock price was $1.52 and its highest was $5.64 in the past 12 months.
What is XTL Biopharmaceuticals Sponsored ADR’s market cap?
XTL Biopharmaceuticals Sponsored ADR’s market cap is $7.81M.
When is XTL Biopharmaceuticals Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XTL Biopharmaceuticals Sponsored ADR’s earnings last quarter?
XTL Biopharmaceuticals Sponsored ADR released its earnings results on Dec 05, 2023. The company reported -$0.039 earnings per share for the quarter.
Is XTL Biopharmaceuticals Sponsored ADR overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does XTL Biopharmaceuticals Sponsored ADR pay dividends?
XTL Biopharmaceuticals Sponsored ADR does not currently pay dividends.
What is XTL Biopharmaceuticals Sponsored ADR’s EPS estimate?
XTL Biopharmaceuticals Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XTL Biopharmaceuticals Sponsored ADR have?
XTL Biopharmaceuticals Sponsored ADR has 4,483,476 shares outstanding.
What happened to XTL Biopharmaceuticals Sponsored ADR’s price movement after its last earnings report?
XTL Biopharmaceuticals Sponsored ADR reported an EPS of -$0.039 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XTL Biopharmaceuticals Sponsored ADR?
Currently, no hedge funds are holding shares in XTLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology